Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms
スポンサーリンク
概要
- 論文の詳細を見る
- 2009-01-01
著者
-
Bacon Kevin
Actimis Pharmaceuticals Inc.
-
Sasik Roman
Biomedical Genomics Microarray Facility (biogem) School Of Medicine University Of California
-
BOEHME Stefen
Actimis Pharmaceuticals, Inc.
-
FRANZ-BACON Karin
Actimis Pharmaceuticals, Inc.
-
CHEN Edward
Actimis Pharmaceuticals, Inc.
-
LY Tai
Actimis Pharmaceuticals, Inc.
-
SPRAGUE L.
Biomedical Genomics Microarray Facility, School of Medicine, University of California
-
HARDIMAN Gary
Biomedical Genomics Microarray Facility, School of Medicine, University of California
-
Ly Tai
Actimis Pharmaceuticals Inc.
-
Franz-bacon Karin
Actimis Pharmaceuticals Inc.
-
Boehme Stefen
Actimis Pharmaceuticals Inc.
-
Chen Edward
Actimis Pharmaceuticals Inc.
-
Hardiman Gary
Biomedical Genomics Microarray Facility (biogem) School Of Medicine University Of California
-
Sprague L.
Biomedical Genomics Microarray Facility (biogem) School Of Medicine University Of California
関連論文
- Murine bone marrow-derived mast cells express chemoattractant receptor-homologous molecule expressed on T-helper class 2 cells (CRT_h2)
- A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation
- Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms